793 TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) human papilloma virus (HPV)-16+ cancers: clinical efficacy and immunogenicity. (9th November 2020)

• Record Type: Journal Article
• Authors: Tourneau, Christophe Le; Cassier, Philippe; Rolland, Frederic; Salas, Sébastien; Limacher, Jean Marc; Capitain, Olivier; Lantz, Olivier; Lalanne, Ana; Ekwegbara, Christina; Tavernaro, Annette; Makhloufi, Hakim; Bendjama, Kaidre; Delord, Jean-Pierre
• Is Part Of: Journal for immunotherapy of cancer. Volume 8(2020)Supplement 3
• Page Start: A474
• Page End: A474
• Publication Date: 2020-11-09
• Subjects: Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2020-SITC2020.0793
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: Specific immune cell responses against oncogenic antigens are major determinants to achieve long-term disease control for HPV-related malignancies. We developed TG4001, a viral based vaccine against the HPV E6 and E7 antigens. Following the demonstration of its safety in phase Ib, we aimed to evaluate the antitumor activity and immune priming effects of TG4001 in combination with the PD-L1 inhibitor avelumab in HPV-related malignancies in phase II (NCT03260023 ). Methods: Patients (pts) with previously treated R/M HPV-16+ cancers received TG4001 at 5x107 pfu SC weekly for 6 weeks, every 2 weeks up to M6, and every 12 weeks thereafter in combination with avelumab IV at 10mg/kg every 2 weeks. PBMC and tissue samples were collected longitudinally prior to and during the treatment period. Specific T cell response was assessed using ex-vivo IFNg-ELISPOT, and changes in the tumor microenvironment by phenotyping of immune infiltrate and transcriptomic analyses of immune related genes. Results: 34 pts with anal (15), oropharyngeal (8), cervical (6) or vulvar/vaginal (5) cancer, were enrolled. Median age was 61 years; the majority (88%) had received at least 1 prior line of chemotherapy (CT) with 32% having received ≥ 2 lines. 8 pts achieved confirmed response according to RECIST 1.1 (1 CR, 7 PR, ORR 23.5%). Responses were observed in all primary tumor types and across all lines of prior therapy. Liver metastases had a profound impact on outcome: ORR was 34.8% and PFS 5.6 months in pts without liver metastases (n=23) versus 0% and PFS of 1.4 months in pts with liver metastases (n=11). Consistent with phase Ib data, the combination had a favorable safety profile. 11 pts were evaluable for T-cell response at day (D) 43. 7/11 patients had vaccine-induced reactive T cells against E6, E7 or both. In particular, in the patient with CR, lesions disappearance was accompanied by the development of a strong T-cell response against E6 and E7. This response developed as early as D43 and sustained at 6 months after initiation of therapy, consistent with the durable disease-control. Increased infiltrates, expression of immune related genes and higher PD-L1 protein expression were observed across all patients suggesting a remodeling of the tumor microenvironment consistent with a switch toward a 'hot tumor' phenotype. Conclusions: Our study suggests that immunotherapeutic combination of TG4001 and avelumab shows valuable tumor activity in pts with previously treated advanced HPV-16+ cancers. These results warrant validation in a larger cohort of patients. Trial Registration: NCT03260023